Baxter Healthcare Sa

Bluesky Immunotherapies Gmbh

Baxalta Gmbh

Nanotherapeutics, Inc.

Blue Sky Vaccines Gmbh

Vivaldi Biosciences Inc.

Markus Wolschek

Thomas Muster

Andrej Egorov

Julia Romanova

Sabine Nakowitsch

Michael Bergmann

Brigitte Krenn

Manfred Reiter

Ales Strancar

Oleg Ivanovich Kiselev

Boris Ferko

Elisabeth Roethl

Mojca Tajnik Sbaizero

Ekaterina Romanovskaya-Romanko

Christian Kittel

Amy Aspelund

Oleg Kiselev

The present invention provides high growth influenza reassortant virus and high growth influenza reassortant virus vectors comprising amino acid modifications in the PB2, PB1, M1 and/or NS2 proteins which exhibit highly increased growth rates compared to unmodified influenza virus. Further provided are pharmaceutical compositions comprising reassortant virus and viral vectors comprising said modifications and their use for vaccination purposes.

Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2

The present invention refers to a process for purifying virus particles from cell culture, comprising the steps of subjecting the cell culture to centrifugation to get a supernatant fraction of virus particles, incubating said fraction with a nuclease, diluting the fraction with low conductivity buffer, subjecting said diluted fraction to a SO3 chromatography step, performing a washing step with low conductivity buffer, and eluting virus particles.

SO3 chromatography for use in a method for virus purification

The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing the influenza virus vector, its use for the treatment of cancer patients and methods for producing the influenza virus vaccine.

Influenza virus vector for virotherapy

The present invention provides a novel influenza virus wherein both the NS and the PB1 gene segments are modified and wherein the PB1-F2 open reading frame is modified by introduction of at least one stop codon. Specifically, the influenza virus is lacking functional NS1 and PB1-F2 proteins. Additionally, a vaccine formulation comprising the modified influenza virus is provided and its use for prevention of influenza vaccination.

Influenza virus

The present invention relates to a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and having a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. The virus can be used as vector for expression of various proteins like chemokines, cytokines or antigenic structures and to produce vaccines. A fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is also provided.

Replication deficient influenza virus for the expression of heterologous sequences

The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.

Method for production of pH stable enveloped viruses

The present invention provides a method for generating negative-strand, segmented RNA viruses using linear expression constructs in the presence of helper virus.

Method for generation of RNA virus

The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus.

The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No. 1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.

Growing community of inventors

Vienna, Austria

Markus Wolschek